
	Year ended May 31,
(in thousands)	2025		2024		2023
Legal (1)	$	715	$	34,942	$	9,998
Mergers and acquisitions (2)	737		399		368
Transition service agreement (3)	(1,838)		(1,092)		—
Plant Closure (4)	13,761		9,481		—
Manufacturing Relocation (5)	—		587		1,091
Intangible and other asset impairment (6)	—		6,260		—
Israeli Innovation Authority prepayment (7)	—		—		3,544
Other (8)	2,245		2,605		632
Total	$	15,620	$	53,182	$	15,633

(1) Legal expenses related to litigation that is outside the normal course of business. For the year ended May 31, 2024, a $19.3 million settlement expense was recorded as a result of the Settlement Agreement that was entered into between the Company and BD.

(4) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.

(6) An impairment of $3.4 million on intangible and fixed assets and an inventory write-off of $2.9 million was taken in the third quarter of fiscal year 2024 relating to the abandonment of the Syntrax and RF product lines.

(7) In the first quarter of fiscal year 2023, a $3.5 million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020.

(8) Included in the $2.2 million and $2.6 million in other for the years ended May 31, 2025 and 2024 is $0.9 million and $1.4 million, respectively, of severance due to restructurings outside of the plant closure. In addition, for the year ended May 31, 2024, $0.9 million of deferred financing fees that were written-off in conjunction with the divestiture of the Dialysis and BioSentry businesses and concurrent extinguishment of the debt.


Type of cost (in thousands)	Total original estimated amount expected to be incurred					Total modified estimated amount expected to be incurred
Facilities closeout fees (1)	$	14,500	to	$	15,250	$	16,000	to	$	17,000
Termination benefits	9,000		to	10,000		6,200		to	7,200
Outside consultants	9,000		to	10,000		7,500		to	8,500
Validation expenses	4,500		to	5,500		3,400		to	4,400
Regulatory filings	750		to	1,250		150		to	650
Other	750		to	1,250		150		to	650
	$	38,500	to	$	43,250	$	33,400	to	$	38,400

(1) Included in the original and modified estimate is approximately $13.6 million and $13.3 million of non-cash charges for accelerated depreciation and building impairment.


	May 31, 2025
	Termination Benefits		Outside Consultants		Validation Expenses		Facilities Closeout Fees		Regulatory Filings		Other		Total
(in thousands)
Balance at May 31, 2024	$	568	$	1,153	$	373	$	—	$	6	$	20	$	2,120
Charges	$	1,555	$	5,646	$	1,769	$	3,381	$	72	$	1,338	$	13,761
Non-cash adjustments	$	—	$	—	$	—	$	(3,381)	$	—	$	—	$	(3,381)
Cash payments	$	(1,494)	$	(6,177)	$	(2,056)	$	—	$	(78)	$	(1,192)	$	(10,997)
Balance at May 31, 2025	$	629	$	622	$	86	$	—	$	—	$	166	$	1,503